Can Price Transparency Contribute to More Affordable Patient Access to Medicines?

PharmacoEconomics - Open

Volumn 1, Issue 3, 2017, Pages 145-147

  Vogler, Sabine ^a   Paterson, Kenneth R ^b  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL;

EID: 85080056701     PISSN: 25094262     EISSN: 25094254     Source Type: Journal    
DOI: 10.1007/s41669-017-0028-1     Document Type: Editorial

References (17)

1. Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU. Brussels: European Parliament; 2011.
2. Vogler S, Lepuschütz L, Schneider P, Stühlinger V. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing. Luxembourg: Gesundheit Österreich Forschungs- und Planungs GmbH; Publications Office of the European Commission; 2016.
3. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.
4. Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Brussels: European Commission, Directorate-General for Economics and Financial Afairs; 2012.
5. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101(15):1044–8.
6. Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from european countries. Appl Health Econ Health Policy. doi:10.1007/s40258-016-0300-z (Epub 6 Jan 2017).
7. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels: EMINet; 2013.
8. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs—evidence from twenty-five major markets in the 1990s. Health Econ. 2005;14(3):269–92.
9. Kyle MK. Pharmaceutical price controls and entry strategies. Rev Econ Stat. 2007;89(1):88–99.
10. Towse A, Pistollato M, Mestre-Ferrandiz J, Khan Z, Kaura S, Garrison L. European Union pharmaceutical markets: a case for differential pricing? Int J Econ Bus. 2015;22(2):263–75.
11. Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):735–41.
12. Vogler S, Zimmermann N, Ferrario A, Wirtz VJ, de Joncheere K, Pedersen HB, et al. Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. J Pharm Policy Pract. 2016;9(1):1.
13. Espín J, Rovira J, Calleja A, Azzopardi-Muscat N, Richardson E, Palm W, et al. How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe? Policy Brief. 2016;21. https://www.eu2017.mt/Documents/Programmes/PB21.pdf. Accessed 8 Apr 2017.
14. Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N. PHIS Hospital Pharma Report. Vienna: Pharmaceutical Health Information System (PHIS); commissioned by the European Commission and the Austrian Federal Ministry of Health; 2010. http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/PHIS_HospitalPharma_Report.pdf. Accessed 2 April 2017.
15. Vogler S, Zimmermann N, Leopold C, Habl C, Mazag J. Discounts and rebates granted for medicines for hospital use in five European countries. Open Pharmacoecon Health Econ J. 2013;5:1–10.
16. van Harten WH, Wind A, de Paoli P, Saghatchian M, Oberst S. Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 2016;17(1):18–20.
17. Morgan S, Vogler S, Wagner AK. Payers’ experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy. 2017;121(4):354–62.